C Lim1, H S Sekhon2, J C Cutz3, D M Hwang4, S Kamel-Reid4,5, R F Carter3,6, G da Cunha Santos4, T Waddell7, M Binnie8, M Patel9, N Paul10, T Chung10, A Brade11, R El-Maraghi12, C Sit13, M S Tsao4, N B Leighl1. 1. Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto. 2. Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa. 3. Department of Pathology and Molecular Medicine, McMaster University, Hamilton. 4. Laboratory Medicine Program, University Health Network, University of Toronto, Toronto. 5. Molecular Diagnostics Laboratory, University Health Network, Toronto. 6. LifeLabs Genetics, Toronto. 7. Division of Thoracic Surgery, University of Toronto, Toronto. 8. Division of Respirology, University of Toronto, Toronto. 9. Division of Respirology, Trillium Health Partners, Mississauga. 10. Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, Toronto. 11. Department of Radiation Oncology, University of Toronto, Toronto. 12. Simcoe Muskoka Regional Cancer Centre, Barrie; and. 13. Lung Cancer Canada, Toronto, ON.
Abstract
BACKGROUND: Although molecular testing has become standard in managing advanced nonsquamous non-small-cell lung cancer (nsclc), most patients undergo minimally invasive procedures, and the diagnostic tumour specimens available for testing are usually limited. A knowledge translation initiative to educate diagnostic specialists about sampling techniques and laboratory processes was undertaken to improve the uptake and application of molecular testing in advanced lung cancer. METHODS: A multidisciplinary panel of physician experts including pathologists, respirologists, interventional thoracic radiologists, thoracic surgeons, medical oncologists, and radiation oncologists developed a specialty-specific education program, adapting international clinical guidelines to the local Ontario context. Expert recommendations from the program are reported here. RESULTS: Panel experts agreed that specialists procuring samples for lung cancer diagnosis should choose biopsy techniques that maximize tumour cellularity, and that conservation strategies to maximize tissue for molecular testing should be used in tissue processing. The timeliness of molecular reporting can be improved by pathologist-initiated reflex testing upon confirmation of nonsquamous nsclc and by prompt transportation of specimens to designated molecular diagnostic centres. To coordinate timely molecular testing and optimal treatment, collaboration and communication between all clinicians involved in diagnosing patients with advanced lung cancer are mandatory. CONCLUSIONS: Knowledge transfer to diagnostic lung cancer specialists could potentially improve molecular testing and treatment for advanced lung cancer patients.
BACKGROUND: Although molecular testing has become standard in managing advanced nonsquamous non-small-cell lung cancer (nsclc), most patients undergo minimally invasive procedures, and the diagnostic tumour specimens available for testing are usually limited. A knowledge translation initiative to educate diagnostic specialists about sampling techniques and laboratory processes was undertaken to improve the uptake and application of molecular testing in advanced lung cancer. METHODS: A multidisciplinary panel of physician experts including pathologists, respirologists, interventional thoracic radiologists, thoracic surgeons, medical oncologists, and radiation oncologists developed a specialty-specific education program, adapting international clinical guidelines to the local Ontario context. Expert recommendations from the program are reported here. RESULTS: Panel experts agreed that specialists procuring samples for lung cancer diagnosis should choose biopsy techniques that maximize tumour cellularity, and that conservation strategies to maximize tissue for molecular testing should be used in tissue processing. The timeliness of molecular reporting can be improved by pathologist-initiated reflex testing upon confirmation of nonsquamous nsclc and by prompt transportation of specimens to designated molecular diagnostic centres. To coordinate timely molecular testing and optimal treatment, collaboration and communication between all clinicians involved in diagnosing patients with advanced lung cancer are mandatory. CONCLUSIONS: Knowledge transfer to diagnostic lung cancer specialists could potentially improve molecular testing and treatment for advanced lung cancerpatients.
Entities:
Keywords:
Non-small-cell lung cancer; biomarkers; knowledge translation; quality of care
Authors: Erik Thunnissen; Keith M Kerr; Felix J F Herth; Sylvie Lantuejoul; Mauro Papotti; Robert C Rintoul; Giulio Rossi; Birgit G Skov; Birgit Weynand; Lukas Bubendorf; Grünberg Katrien; Leif Johansson; Fernando López-Ríos; Vincent Ninane; Włodzimierz Olszewski; Helmut Popper; Sauleda Jaume; Philipp Schnabel; Luc Thiberville; Florian Laenger Journal: Lung Cancer Date: 2011-12-03 Impact factor: 5.705
Authors: Brian T Collins; Alexander C Chen; Jeff F Wang; Cory T Bernadt; Souzan Sanati Journal: Cancer Cytopathol Date: 2013-07-03 Impact factor: 5.284
Authors: Alda L Tam; Edward S Kim; J Jack Lee; Joe E Ensor; Marshall E Hicks; Ximing Tang; George R Blumenschein; Christine M Alden; Jeremy J Erasmus; Anne Tsao; Scott M Lippman; Waun K Hong; Ignacio I Wistuba; Sanjay Gupta Journal: J Thorac Oncol Date: 2013-04 Impact factor: 15.609
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Chimbu Chinniah; Louise Aguarin; Phillip Cheng; Cristina Decesaris; Alicia Cutillo; Abigail T Berman; Melissa Frick; Abigail Doucette; Keith A Cengel; William Levin; Stephen Hahn; Jay F Dorsey; Charles B Simone; Gary D Kao Journal: Clin Lung Cancer Date: 2019-05-04 Impact factor: 4.785
Authors: Zhicheng Jiao; Hongming Li; Ying Xiao; Jay Dorsey; Charles B Simone; Steven Feigenberg; Gary Kao; Yong Fan Journal: Int J Radiat Oncol Biol Phys Date: 2021-11-11 Impact factor: 8.013
Authors: Maisam Makarem; Doreen A Ezeife; Adam C Smith; Janice J N Li; Jennifer H Law; Ming-Sound Tsao; Natasha B Leighl Journal: Curr Oncol Date: 2021-08-25 Impact factor: 3.677
Authors: Zhicheng Jiao; Hongming Li; Ying Xiao; Charu Aggarwal; Maya Galperin-Aizenberg; Daniel Pryma; Charles B Simone; Steven J Feigenberg; Gary D Kao; Yong Fan Journal: Int J Radiat Oncol Biol Phys Date: 2021-01-19 Impact factor: 7.038
Authors: P Garrido; E Conde; J de Castro; J J Gómez-Román; E Felip; L Pijuan; D Isla; J Sanz; L Paz-Ares; F López-Ríos Journal: Clin Transl Oncol Date: 2019-10-09 Impact factor: 3.405